The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. announced that CEO Dr. Shankar Musunuri and Abhi Gupta, Executive Vice President of Commercial and Business Development, will present at international biotech conferences on April 28.
The company plans to share updates on its gene therapy platform and detail progress towards its initial Biologics License Application (BLA) submission and subsequent commercialization strategy. The participation in prominent industry events signals Ocugen, Inc.'s ongoing commitment to advancing next-generation therapies and expanding its commercial reach.
Ocugen, Inc. has previously focused on developing gene therapies targeting hundreds of mutations to address a global vision loss burden estimated at $132 billion, according to company disclosures. The firm has also credited retinal surgeons for clinical progress in modifier gene therapy aimed at major blindness diseases, as noted in prior reports. These initiatives form the foundation for Ocugen's ongoing therapeutic and commercial development.